- Research works
- 1 fractional, all time
- Citations
- 70 63.1 per fractional work
- Top-10% rate
- 0.0% record average 16.5%
- Open access
- 70% world 28%
Not ranked overall: ImmuPharma (France) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Which research topics does ImmuPharma (France) publish most on?
By volume in 2022–2025: Chemical Synthesis and Analysis, Cancer-related gene regulation, Antimicrobial Peptides and Activities and Glycosylation and Glycoproteins Research.
- 1 Chemical Synthesis and Analysis Molecular Biology 0 works
- 2 Cancer-related gene regulation Molecular Biology 0 works
- 3 Antimicrobial Peptides and Activities Microbiology 0 works
- 4 Glycosylation and Glycoproteins Research Molecular Biology 0 works
- 5 Click Chemistry and Applications Organic Chemistry 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has ImmuPharma (France)'s research output changed?
Other research institutions in Mulhouse
- Université de Haute-Alsace
- Laboratoire de Photochimie et d'Ingénierie Macromoléculaire
- Institut de Sciences des Matériaux de Mulhouse
- Centre Hospitalier de Mulhouse
- Groupe Hospitalier de la Région de Mulhouse et Sud Alsace
- Institut de Recherche en Hématologie et Transplantation
- Hôpital du Hasenrain
- Rhenovia (France)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.